As a result, clinical trials using recombinant TRAIL or its agonistic antibodies against DR4 or DR5 as a single agent or in combination with clinically used chemotherapeutic agents were initiated in patients with different cancers [44, 45]. The gene discussed is TNFRSF10B; the disease is cancer.